Davies Sarah D, Ochs Mark W
Department of Oral and Maxillofacial Surgery, University of Pittsburgh School of Dental Medicine, 3471 Fifth Avenue, Suite 1112, UPMC Kaufman Building, Pittsburgh, PA 15213, USA.
Oral Maxillofac Surg Clin North Am. 2010 Feb;22(1):17-31. doi: 10.1016/j.coms.2009.10.007.
Craniomaxillofacial surgery has many indications for bone regeneration and augmentation, ranging from socket preservation to reconstruction of large skeletal defects. The discovery of bone morphogenetic proteins (BMPs) as osteoinductive agents and the subsequent development of commercially available recombinant forms of BMPs have offered the potential to replace traditional grafting techniques with de novo bone formation. Extensive preclinical and clinical research has focused on establishing the safety and efficacy of using recombinant BMPs to regenerate bone in the facial skeleton. This article reviews the development and current scientific basis behind the use of these new biologics.
颅颌面外科有许多骨再生和骨增量的适应证，范围从牙槽窝保存到大型骨骼缺损的重建。骨形态发生蛋白（BMPs）作为骨诱导剂的发现以及随后市售重组形式BMPs的开发，为用新骨形成替代传统移植技术提供了可能性。广泛的临床前和临床研究集中于确定使用重组BMPs在面部骨骼中再生骨的安全性和有效性。本文综述了这些新型生物制剂使用背后的发展历程和当前科学依据。
